{"id":"brentuximab-vedotin-induction","safety":{"commonSideEffects":[{"rate":"40-50%","effect":"Neutropenia"},{"rate":"20-30%","effect":"Thrombocytopenia"},{"rate":"20-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1742994","moleculeType":"Antibody drug conjugate"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by binding to CD30 and delivering a toxic agent, monomethyl auristatin E, into the cell, leading to cell death. This targeted approach helps minimize damage to healthy cells.","oneSentence":"Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:58:00.318Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hodgkin lymphoma"},{"name":"Anaplastic large cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06393361","phase":"PHASE2","title":"Chidamide Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-06-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT06507514","phase":"PHASE1","title":"Blinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-04-01","conditions":"B-cell Acute Lymphoblastic Leukemia","enrollment":4},{"nctId":"NCT03113500","phase":"PHASE2","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-05-25","conditions":"Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":48},{"nctId":"NCT07013565","phase":"PHASE2","title":"Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York Medical College","startDate":"2025-08-07","conditions":"Anaplastic Large Cell Lymphoma, ALK-Positive","enrollment":20},{"nctId":"NCT03233347","phase":"PHASE2","title":"Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2017-10-13","conditions":"Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma","enrollment":82},{"nctId":"NCT03719105","phase":"EARLY_PHASE1","title":"Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2019-03-01","conditions":"NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma","enrollment":40},{"nctId":"NCT03496779","phase":"PHASE2","title":"Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2018-04-10","conditions":"Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma","enrollment":71},{"nctId":"NCT07074457","phase":"NA","title":"Chidamide Combined With Brentuximab Vedotin Regimen for CD30+ PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":"CD30+ Peripheral T-cell Lymphoma","enrollment":47},{"nctId":"NCT05253495","phase":"PHASE2","title":"Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2022-02-01","conditions":"Non-hodgkin Lymphoma, Hodgkin Lymphoma","enrollment":80},{"nctId":"NCT03264131","phase":"PHASE2","title":"BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-10-11","conditions":"Lymphoma, Adult T-Cell Leukemia/Lymphoma, Lymphatic Diseases","enrollment":16},{"nctId":"NCT03703050","phase":"PHASE2","title":"Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-01-02","conditions":"Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma","enrollment":45},{"nctId":"NCT06563778","phase":"PHASE2","title":"Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-09-01","conditions":"Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma","enrollment":100},{"nctId":"NCT03217643","phase":"PHASE2","title":"CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.","status":"COMPLETED","sponsor":"Imagine Institute","startDate":"2018-02-07","conditions":"Enteropathy Associated T-cell Lymphoma","enrollment":14},{"nctId":"NCT04378647","phase":"PHASE2","title":"BREntuximab Vedotin in SEcond LIne Therapy BEfore Transplant","status":"RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2020-06-01","conditions":"Hodgkin Lymphoma, Adult","enrollment":150},{"nctId":"NCT05444712","phase":"NA","title":"Transplantation After Complete Response In Patients With T-cell Lymphoma","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2022-08-01","conditions":"Peripheral T Cell Lymphoma","enrollment":204},{"nctId":"NCT04138875","phase":"PHASE2","title":"A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-01","conditions":"PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer","enrollment":""},{"nctId":"NCT05349383","phase":"","title":"Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities","status":"COMPLETED","sponsor":"Central South University","startDate":"2022-04-22","conditions":"Sepsis (SMQ), Opportunistic Infections, Agranulocytosis","enrollment":24618},{"nctId":"NCT01578967","phase":"NA","title":"Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2012-04","conditions":"Hodgkin Lymphoma, Adult","enrollment":41},{"nctId":"NCT01805037","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2013-03-05","conditions":"Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma","enrollment":20},{"nctId":"NCT02298283","phase":"PHASE2","title":"Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2015-04","conditions":"Hodgkin Lymphoma","enrollment":40},{"nctId":"NCT01830777","phase":"PHASE1","title":"Brentuximab Vedotin + Re-induction Chemotherapy for AML","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2013-05","conditions":"Acute Myelogenous Leukemia","enrollment":22},{"nctId":"NCT02243436","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2014-11-11","conditions":"CLASSICAL HODGKIN LYMPHOMA","enrollment":67},{"nctId":"NCT01900496","phase":"PHASE1","title":"Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-06","conditions":"Lymphoma","enrollment":6},{"nctId":"NCT02244021","phase":"PHASE2","title":"BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in R/R HL Patients Non Responding to IGEV","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2014-12","conditions":"Relapsed/Refractory Hodgkin's Lymphoma","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Adcetris"],"phase":"phase_2","status":"active","brandName":"Brentuximab Vedotin - induction","genericName":"Brentuximab Vedotin - induction","companyName":"The Lymphoma Academic Research Organisation","companyId":"the-lymphoma-academic-research-organisation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brentuximab vedotin is a monoclonal antibody-drug conjugate that targets CD30, a protein often found on the surface of Hodgkin lymphoma and anaplastic large cell lymphoma cells. Used for Hodgkin lymphoma, Anaplastic large cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}